Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GRK5 | P34947 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phetharbital SCHEMBL78655 | 0.80 | ELANE (0.71) | ELANELMNANPSR1GRK5TYRO3 | |
| SCHEMBL826295 | 0.70 | ELANE (0.44) | ELANELMNAITGA4ITGB7ALDH1A1 | |
| SCHEMBL30385072 | 0.70 | ELANE (0.44) | ELANELMNAITGA4ITGB7ALDH1A1 | |
| SCHEMBL19184961 | 0.70 | ELANE (0.73) | ELANEALDH1A1MAPK1CYP2C19 | |
| SCHEMBL17716269 | 0.70 | ELANE (0.73) | ELANEALDH1A1MAPK1CYP2C19 | |
| SCHEMBL16865399 | 0.70 | ELANE (0.55) | ELANELMNAALDH1A1MAPTKDM4E | |
| SCHEMBL17716273 | 0.68 | ELANE (0.89) | ELANENPSR1 | |
| SCHEMBL11465842 | 0.68 | AR (0.68) | ELANELMNAKMT2AMEN1POLB | |
| SCHEMBL17716644 | 0.68 | ELANE (0.46) | ELANEALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL16865421 | 0.68 | ELANE (0.42) | ELANELMNAALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716315-B2 | Analogs of thalidomide as potential angiogenesis inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-05-06 | — | — | US | disclosed |
| US-8143252-B2 | Tetrahalogenated compounds useful as inhibitors of angiogenesis | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090186913-A1 | Tetrahalogenated compounds useful as inhibitors of angiogenesis | THE GOVERNMENT OF THE UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2009-07-23 | — | — | US | disclosed |
| US-7320991-B2 | Analogs of thalidomide as potential angiogenesis inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070293519-A1 | Analogs of thalidomide as potential angiogenesis inhibitors | THE GOVT. OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2007-12-20 | — | — | US | disclosed |
| US-20040077685-A1 | Analogs of thalidomide as potential angiogenesis inhibitors | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF | 2004-04-22 | — | — | US | disclosed |
| WO-2002068414-A3 | ANALOGS OF THALIDOMIDE AS POTENTIAL ANGIOGENESIS INHIBITORS | GOVERNEMENT OF THE UNITED STAT (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077685-A1 | Analogs of thalidomide as potential angiogenesis inhibitors | FLT4, TEK, VEGFA | ELANE 1923/4885LMNA 4787/4885ITGA4 3988/4885 |
| US-20070293519-A1 | Analogs of thalidomide as potential angiogenesis inhibitors | FLT4, TEK, VEGFA | ELANE 1928/4885LMNA 4820/4885ITGA4 4054/4885 |
| US-20090186913-A1 | Tetrahalogenated compounds useful as inhibitors of angiogenesis | VHL, TEK, FLT4 | ELANE 438/4885LMNA 4761/4885ITGA4 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.